Conclusion
Targeting the IL-5/IL-5Rα axis is an effective strategy to prevent the
AHR. Benralizumab resulted more potent than the mepolizumab and the
concentration dependent beneficial effects of both these agents were
related with improved levels of cAMP in hyperresponsive airways.